Perrigo CEO defends Elan acquisition
This article was originally published in Scrip
When news of Perrigo's friendly acquisition offer for Elan hit the news wires on the morning of 29 July, the over-riding reaction from observers was one of confusion. Why was this a good deal for Perrigo? Surely it could have taken advantage of the Irish tax system through the more cheaper option of relocating domicile to Ireland, just as Shire did a few years ago, rather than paying out cash and stock of $8.6bn (scripintelligence.com, 29 July 2013)?
You may also be interested in...
Perrigo Puts Tysabri On Block, Generic Topicals Under Microscope
A portfolio review concluded that 'the next step to unlock shareholder value is … exploring strategic alternatives for that Tysabri royalty stream,' CEO John Hendrickson said during Perrigo's third-quarter earnings briefing.
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.